CA3075443A1 - Abx196 for use in the treatment of bladder cancer - Google Patents
Abx196 for use in the treatment of bladder cancer Download PDFInfo
- Publication number
- CA3075443A1 CA3075443A1 CA3075443A CA3075443A CA3075443A1 CA 3075443 A1 CA3075443 A1 CA 3075443A1 CA 3075443 A CA3075443 A CA 3075443A CA 3075443 A CA3075443 A CA 3075443A CA 3075443 A1 CA3075443 A1 CA 3075443A1
- Authority
- CA
- Canada
- Prior art keywords
- bladder
- abx196
- treatment
- antibody
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306182.1 | 2017-09-13 | ||
| EP17306182 | 2017-09-13 | ||
| PCT/EP2018/074778 WO2019053142A1 (en) | 2017-09-13 | 2018-09-13 | ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075443A1 true CA3075443A1 (en) | 2019-03-21 |
Family
ID=60001797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075443A Pending CA3075443A1 (en) | 2017-09-13 | 2018-09-13 | Abx196 for use in the treatment of bladder cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11266667B2 (enExample) |
| EP (1) | EP3681512B1 (enExample) |
| JP (1) | JP7214718B2 (enExample) |
| KR (1) | KR102706165B1 (enExample) |
| CN (1) | CN111182907B (enExample) |
| AU (1) | AU2018332046B2 (enExample) |
| BR (1) | BR112020004778A2 (enExample) |
| CA (1) | CA3075443A1 (enExample) |
| CU (1) | CU20200020A7 (enExample) |
| DK (1) | DK3681512T3 (enExample) |
| ES (1) | ES2893549T3 (enExample) |
| HR (1) | HRP20211351T1 (enExample) |
| IL (1) | IL273054B2 (enExample) |
| MX (1) | MX394216B (enExample) |
| PL (1) | PL3681512T3 (enExample) |
| PT (1) | PT3681512T (enExample) |
| WO (1) | WO2019053142A1 (enExample) |
| ZA (1) | ZA202001435B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0820960B8 (pt) * | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| US9220767B2 (en) | 2008-10-08 | 2015-12-29 | Abivax | Vaccine composition for use against influenza |
| JP6057300B2 (ja) | 2011-01-05 | 2017-01-11 | ナショナル タイワン ユニバーシティ | グリコスフィンゴ脂質の調製及びその使用の方法 |
| WO2018050782A1 (en) | 2016-09-14 | 2018-03-22 | Abivax | Combinations including abx196 for the treatment of cancer |
-
2018
- 2018-09-13 CA CA3075443A patent/CA3075443A1/en active Pending
- 2018-09-13 EP EP18765477.7A patent/EP3681512B1/en active Active
- 2018-09-13 WO PCT/EP2018/074778 patent/WO2019053142A1/en not_active Ceased
- 2018-09-13 US US16/647,379 patent/US11266667B2/en not_active Expired - Fee Related
- 2018-09-13 KR KR1020207007414A patent/KR102706165B1/ko active Active
- 2018-09-13 MX MX2020002812A patent/MX394216B/es unknown
- 2018-09-13 CU CU2020000020A patent/CU20200020A7/es unknown
- 2018-09-13 JP JP2020515026A patent/JP7214718B2/ja active Active
- 2018-09-13 ES ES18765477T patent/ES2893549T3/es active Active
- 2018-09-13 CN CN201880064390.5A patent/CN111182907B/zh active Active
- 2018-09-13 DK DK18765477.7T patent/DK3681512T3/da active
- 2018-09-13 PT PT18765477T patent/PT3681512T/pt unknown
- 2018-09-13 PL PL18765477T patent/PL3681512T3/pl unknown
- 2018-09-13 BR BR112020004778-3A patent/BR112020004778A2/pt active Search and Examination
- 2018-09-13 HR HRP20211351TT patent/HRP20211351T1/hr unknown
- 2018-09-13 AU AU2018332046A patent/AU2018332046B2/en not_active Ceased
-
2020
- 2020-03-04 IL IL273054A patent/IL273054B2/en unknown
- 2020-03-06 ZA ZA2020/01435A patent/ZA202001435B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20211351T1 (hr) | 2021-11-26 |
| EP3681512B1 (en) | 2021-08-04 |
| BR112020004778A2 (pt) | 2020-10-13 |
| JP2020533368A (ja) | 2020-11-19 |
| MX394216B (es) | 2025-03-24 |
| AU2018332046A1 (en) | 2020-03-19 |
| JP7214718B2 (ja) | 2023-01-30 |
| KR20200102412A (ko) | 2020-08-31 |
| PL3681512T3 (pl) | 2022-01-17 |
| CN111182907A (zh) | 2020-05-19 |
| US20200230163A1 (en) | 2020-07-23 |
| MX2020002812A (es) | 2020-07-21 |
| RU2020109889A3 (enExample) | 2022-01-28 |
| CU20200020A7 (es) | 2020-11-30 |
| AU2018332046B2 (en) | 2024-06-13 |
| IL273054B2 (en) | 2023-05-01 |
| IL273054A (en) | 2020-04-30 |
| EP3681512A1 (en) | 2020-07-22 |
| US11266667B2 (en) | 2022-03-08 |
| PT3681512T (pt) | 2021-10-06 |
| KR102706165B1 (ko) | 2024-09-13 |
| RU2020109889A (ru) | 2021-09-06 |
| ZA202001435B (en) | 2022-07-27 |
| IL273054B1 (en) | 2023-01-01 |
| ES2893549T3 (es) | 2022-02-09 |
| WO2019053142A1 (en) | 2019-03-21 |
| CN111182907B (zh) | 2023-01-06 |
| DK3681512T3 (da) | 2021-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| CN101972478B (zh) | 抗体治疗 | |
| CN108602891A (zh) | 治疗尿道恶性肿瘤的多特异性抗体 | |
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| US11826372B2 (en) | Combinations including ABX196 for the treatment of cancer | |
| CN114026126A (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| US20240043543A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| CN113038939A (zh) | 损害内施用pd-1抑制剂用于治疗皮肤癌 | |
| AU2018332046B2 (en) | ABX196 for use in the treatment of bladder cancer | |
| RU2778812C2 (ru) | Abx196 для применения при лечении рака мочевого пузыря | |
| CA3036598C (en) | Combinations including abx196 for the treatment of cancer | |
| HK40011701B (en) | Combinations including abx196 for the treatment of cancer | |
| HK40011701A (en) | Combinations including abx196 for the treatment of cancer | |
| WO2023174278A1 (zh) | 抗tim-3抗体与去甲基化药物的药物组合 | |
| CN121152804A (zh) | 用抗mica/b抗体治疗癌症的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230814 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240829 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240829 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250609 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250609 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251024 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251028 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260504 |